Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Aschaffenburg – page 74

1 096 clinical trials in Aschaffenburg, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Aschaffenburg at a glance
1 096
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 096 trials in Aschaffenburg

Open in trial search

Follicular lymphoma

Not recruiting

Study on Mosunetuzumab and Lenalidomide for Patients with Untreated Follicular Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:LYSARC

Asthmatic crisis

Not recruiting

Study on the Effects of Verekitug (UPB-101) for Adults with Severe Asthma

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Upstream Bio Inc.

Study of Lacutamab Alone or with Chemotherapy for Patients with Advanced T-Cell Lymphoma

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lacutamab
  • Sponsor:Innate Pharma

Hereditary angioedema

Not recruiting

Long-term safety study of garadacimab (CSL312) for prevention of hereditary angioedema attacks

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:CSL Behring LLC

Soft tissue sarcoma

Not recruiting

Study on L19TNF and Doxorubicin for Patients with Advanced or Metastatic Soft Tissue Sarcoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Onfekafusp Alfa
  • Sponsor:Philogen S.p.A.

Diabetic nephropathy

Not recruiting

Study on the Effectiveness and Safety of Finerenone and Empagliflozin in Adults with Chronic Kidney Disease and Type 2 Diabetes

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Empagliflozin
  • Sponsor:Bayer AG

Sepsis+1

Not recruiting

Study on the Safety and Effectiveness of TIN816 for Patients with Sepsis-Related Acute Kidney Injury

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:TIN816
  • Sponsor:Novartis Pharma AG

Chronic hepatitis B+1

Not recruiting

Study on Safety and Efficacy of Bepirovirsen and Drug Combination for Chronic Hepatitis B in Patients on Nucleos(t)ide Analogue Therapy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Bepirovirsen
  • Sponsor:GlaxoSmithKline Biologicals

Hidradenitis

Not recruiting

Study on the Effectiveness of Ianalumab for Treating Moderate to Severe Hidradenitis Suppurativa in Patients

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ianalumab
  • Sponsor:Novartis Pharma AG

Ovarian cancer

Not recruiting

Study on Niraparib for Maintenance Treatment in Patients with Advanced Ovarian Cancer After Initial Chemotherapy Response

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Tesaro Inc.

Study Comparing Asciminib with Other Drug Combinations for Adults with Newly Diagnosed Chronic Myeloid Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bosutinib
  • Sponsor:Novartis Pharma AG

Hidradenitis

Not recruiting

Study on the Long-Term Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Other cities in Germany

The busiest research cities in the country

All 503 cities in Germany

Clinical research in Aschaffenburg

What the registry says about research in the country

01 Hematologic Oncology

Groundbreaking research focusing on acute myeloid leukemia and chronic lymphocytic leukemia, evaluating novel therapeutic approaches including targeted therapies and combination treatments. Studies examine innovative drug combinations to improve patient outcomes in various blood cancers.

  • FLT3-mutation targeted therapies
  • Chemotherapy optimization
  • Novel drug combinations

Multiple trials investigating treatments for both newly diagnosed and relapsed/refractory patients.

02 Breast Cancer Research

Advanced studies in hormone receptor-positive breast cancer, particularly focusing on metastatic disease. Investigations include new combination therapies and targeted treatments for patients with specific genetic mutations.

  • ESR1-mutation treatments
  • CDK4/6 inhibitor combinations
  • Endocrine therapy resistance

Research emphasizes personalized treatment approaches based on molecular profiles.

03 Respiratory Medicine

Innovative research in severe asthma treatment, particularly focusing on patients with eosinophilic phenotype. Studies evaluate new biological therapies and compare their efficacy with existing treatments.

  • Anti-IL-5/5R therapy
  • Long-term efficacy studies
  • Phenotype-specific treatments

Trials aim to improve long-term management of severe respiratory conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.